The Journal of
Clinical Psychiatry

Depression (MDD)

Insights April 6, 2021

Talking With Patients Who Have Major Depressive Disorder About the Benefits and Risks Associated With Atypical Antipsychotics

Roueen Rafeyan, MD, DFAPA, FASAM ; George I. Papakostas, MD ; W. Clay Jackson, MD, DipTh ; Madhukar H. Trivedi, MD

J Clin Psychiatry 2020;81(3):OT19037BR3

Learn how to talk with patients who have major depressive disorder about antipsychotic treatment in a way that is clear and balanced and addresses patients’ potential concerns about taking antipsychotic medication.

Read the eReport

Save

Cite

INFORMATION FROM INDUSTRY

AUVELITY is an FDA-approved treatment for adults with MDD. Auvelity, is a rapid-acting antidepressant with a multimodal mechanism, targeting both glutamatergic and monoaminergic pathways. Learn more about how AUVELITY is thought to work and side effects. Please see Important Safety Information within this document and the full Prescribing Information.

Vol 86 • 2025 • Number 1

Read the Current Issue

Original Research

Psychological Support in Psychedelic Therapy

Original Research

Long-Term Safety and Efficacy of Esmethadone in MDD

Original Research

Suicidal Behaviors and Obstructive Sleep Apnea

Editorial

A Collaborative Endeavor

Brief Report

Sex Differences in PTSD among US Military Veterans

Clinical and Practical Psychopharmacology

Cannabis Use During Pregnancy and Neuropsychiatric Adverse Outcomes in Children and Young Adults

View current Issue

Insights

Patient Functioning and Life Engagement: Treatment Goals in MDD

September 7, 2022

Patients with MDD often report lack of motivation and energy and a feeling of disengagement from their own lives. Here, experts discuss treatment strategies that may be favorable for...

Christoph U. Correll , Zahinoor Ismail , Roger S. McIntyre , et al

Insights

Measurement-Based Care for Depressive Disorders: Meta-Analysis of RCTs Shows Efficacy

May 17, 2022

Dr Lam explains in this video how for patients with depressive disorders treated with pharmacotherapy, measurement-based care is effective in decreasing symptom severity, promoting remission, and improving medication adherence.

Raymond W. Lam

Insights

Progression of Symptoms Over the Course of Bipolar Disorder

April 13, 2021

Dr Joseph F. Goldberg discusses how symptoms and clinical presentation change over time in people with bipolar disorder, beginning from the prodromal phase

Joseph F. Goldberg

Talking With Patients Who Have Major Depressive Disorder About the Benefits and Risks Associated With Atypical Antipsychotics

Read the Current Issue

Psychological Support in Psychedelic Therapy

Long-Term Safety and Efficacy of Esmethadone in MDD

Suicidal Behaviors and Obstructive Sleep Apnea

A Collaborative Endeavor

Sex Differences in PTSD among US Military Veterans

Cannabis Use During Pregnancy and Neuropsychiatric Adverse Outcomes in Children and Young Adults

ELSEWHERE:

FOLLOW US:

Talking With Patients Who Have Major Depressive Disorder About the Benefits and Risks Associated With Atypical Antipsychotics

Read the Current Issue

Psychological Support in Psychedelic Therapy

Long-Term Safety and Efficacy of Esmethadone in MDD

Suicidal Behaviors and Obstructive Sleep Apnea

A Collaborative Endeavor

Sex Differences in PTSD among US Military Veterans

Cannabis Use During Pregnancy and Neuropsychiatric Adverse Outcomes in Children and Young Adults

Related Articles

Patient Functioning and Life Engagement: Treatment Goals in MDD

Measurement-Based Care for Depressive Disorders: Meta-Analysis of RCTs Shows Efficacy

Progression of Symptoms Over the Course of Bipolar Disorder

Watch the New PsychCase360

Subscribe to readmore articles

Subscribe to read
more articles